GSK 1995057

Drug Profile

GSK 1995057

Alternative Names: GSK1995057

Latest Information Update: 02 May 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antibodies
  • Mechanism of Action Type 1 tumour necrosis factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome

Most Recent Events

  • 30 Sep 2012 GlaxoSmithKline completes a phase I trial in Healthy volunteers in United Kingdom (NCT01587807)
  • 30 Apr 2012 GlaxoSmithKline completes a phase I trial in Healthy volunteers in United Kingdom (NCT01476046)
  • 31 Mar 2012 Phase-I clinical trials in Adult respiratory distress syndrome in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top